Journal of Clinical Psychopharmacology · 1985 · 13 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepression ManagementDepression PharmacotherapyAnticholinergic DrugsAntidepressant Drug ClassesAntidepressant MedicationsAntidepressant ResponseAntidepressant SafetyDouble-blind TrialsMajor DepressionMemory Test
Forty-two outpatients with major depression were treated in a 4-week double-blind parallel-group comparison of the new antidepressant clovoxamine--a member of oximethers of aralkylketones--with amitriptyline. The two drugs were comparable in efficacy, although because of the small sample size a moderate clinical difference between treatments may not have been detected. The magnitude of unwanted effects also was comparable, but clovoxamine produced fewer "anticholinergic" effects; this was determined by patient complaints of typical anticholinergic symptoms, by decreased salivary flow, and by a new signal detection memory test.